$BBI News

Last published 2y ago

2y agoCRI FND LIN BBISpruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Floor & Decor Holdings, Inc. (NYSE: FND)Business WireNOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New
4y agoBBI FRTXFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02GlobeNewswireFRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept.
4y agoBBIBrickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsGlobeNewswireNew name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Comp
4y agoBBIBrickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors
4y agoBBIBrickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022GlobeNewswireBOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for th
4y agoBBIBrickell Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireBOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for th
4y agoBBIBrickell Biotech to Participate at William Blair Biotech Focus Conference 2022GlobeNewswireBOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription th
4y agoBBIBrickell Biotech Announces 1-For-45 Reverse Stock SplitGlobeNewswireBOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription th
4y agoBBIBrickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02GlobeNewswire– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 s
4y agoBBI SYNHA Safety, Tolerability and Preliminary Efficacy Study of BBI-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis - NCT05382819ClinicalTrials.govThe number of participants with treatment-emergent adverse events.
4y agoBBIBrickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments
4y agoBBIBrickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022GlobeNewswireBOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the
4y agoAQST BBI IMMP INDO+1Thinking about buying stock in Immutep, Brickell Biotech, Indonesia Energy, TG Therapeutics, or Aquestive Therapeutics?PR NewswireNEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMP, BBI, INDO, TGTX, and AQST. To
4y agoBBIBrickell Biotech Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireMeeting adjourned to May 17, 2022 at 10 a.m. MT Brickell encourages all stockholders of record on March 7, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on May 16, 2022 BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Brickell
4y agoBBIBrickell Biotech Announces Sale of Sofpironium Bromide to Botanix PharmaceuticalsGlobeNewswireDeal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell Sale reflects Brickell's
4y agoBBI CEI HNRG SAVA+1Thinking about buying stock in Toughbuilt Industries, Camber Energy, Hallador Energy, Brickell Biotech, or Cassava Sciences?PR NewswireNEW YORK, April 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, CEI, HNRG, BBI, and SAVA. To
4y agoBBIBrickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireBroadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor plat
4y agoBBIBrickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual MeetingGlobeNewswireBOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription t
4y agoBBIBrickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022GlobeNewswireBOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription t
4y agoBBIBrickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna BiosciencesGlobeNewswireLead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism Agreement enhances Brickell's pipeline in immunology and inflammation and leverages
4y agoBBI BBIG BKKT OPEN+1Thinking about buying stock in Vinco Ventures, Brickell Biotech, Vale SA, Opendoor Technologies, or Bakkt?PR NewswireNEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, BBI, VALE, OPEN, and BKKT.
4y agoBBI MRO NKLA XXII+1Thinking about buying stock in Brickell Biotech, Zynga, 22nd Century Group, Nikola Corp, or Marathon Oil?PR NewswireNEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBI, ZNGA, XXII, NKLA, and MRO. T
5y agoBBIBrickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Development of DYRK1A inh
5y agoBBIBrickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021GlobeNewswireBOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for th
5y agoBBIBrickell Biotech Prices Public Offering of Common StockGlobeNewswireBOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (NASDAQ:BBI) ("Brickell"), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for th
5y agoBBIBrickell Biotech Announces Proposed Underwritten Public Offering of Common StockGlobeNewswireBOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (NASDAQ:BBI) ("Brickell"), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for th
5y agoBBI BTBT CEI OSMT+1Thinking about buying stock in Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, or SmileDirectClub?PR NewswireNEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, BTBT, BBI, OSMT, and SDC. To s
5y agoBBIBrickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis PatientsGlobeNewswireSofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Management to host webcast and conference call today at 8:30 a.m. ET to present the topline results BOULDER, Colo.
5y agoBBIBrickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in AutoimmunityGlobeNewswireBOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for t
5y agoBBIBrickell Biotech to Participate at Upcoming September ConferencesGlobeNewswireBOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for t
5y agoBBIBrickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical OfficerGlobeNewswireBOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription t
5y agoBBIBrickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory DiseasesGlobeNewswireExpect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes rights to platform of DYRK1A inhibitors with potential
5y agoBBIBrickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary HyperhidrosisGlobeNewswireTopline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 NDA submission for sofpironium bromide gel, 15% anticipated in mid-2022 pending Phase 3 outcome BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIR
5y agoBBIBrickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireFinal patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021- - -Recent $8.1 mill
5y agoBBIBrickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021GlobeNewswireBOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating
5y agoBBIBrickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter's Option to Purchase Additional SharesGlobeNewswireBOULDER, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (NASDAQ:BBI) (the "Company" or "Brickell"), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment
5y agoBBIBrickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 MillionGlobeNewswireBOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (NASDAQ:BBI) (the "Company" or "Brickell"), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment o
5y agoBBIBrickell Biotech Announces $5.0 Million Bought Deal Offering of Common StockGlobeNewswireBOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (NASDAQ:BBI) ("Brickell" or the "Company"), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment
5y agoBBIBrickell Biotech to Participate at William Blair's Biotech Focus Conference 2021GlobeNewswireBOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating
5y agoBBI BLIN VERB VTNR+1Thinking about buying stock in Vertex Energy, Exela Technologies, Bridgeline Digital, Verb Technology, or Brickell Biotech?PR NewswireNEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTNR, XELA, BLIN, VERB, and BBI. T
5y agoBBIBrickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary HyperhidrosisGlobeNewswireBOULDER, Colo., June 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment
5y agoBBIBrickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in JapanGlobeNewswireBOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment
5y agoBBIBrickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of DermatologyGlobeNewswireBOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating
5y agoBBIBrickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021- - -Presented results from Phase 3 op
5y agoBBIBrickell Biotech Inc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 13, 2021 / Brickell Biotech Inc (NASDAQ:BBI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a
5y agoBBIBrickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021GlobeNewswireBOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating
5y agoBBIBrickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary HyperhidrosisGlobeNewswirePhase 3 Pivotal Cardigan II study exceeds 50% enrollment- - -Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 BOULDER, Colo., April 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or
5y agoBBIBrickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary HyperhidrosisGlobeNewswireDaily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment Data presented to
5y agoBBIBrickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMXGlobeNewswireBOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...
5y agoBBIBrickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in DermatologyGlobeNewswireBOULDER, Colo., April 15, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and...